Skip to main content
SpringerLink
Log in

Is Resection of Persistent N2 Disease After Induction Therapy Effective?

  • Chapter
  • First Online:
Difficult Decisions in Thoracic Surgery

Part of the book series: Difficult Decisions in Surgery: An Evidence-Based Approach ((DDSURGERY))

Abstract

Non-small cell lung cancer patients with N2 disease should be treated with induction therapy. The feasibility of potential surgery should be assessed prior to starting induction therapy. Surgical resection should only be considered for acceptable surgical candidates with single-station mediastinal nodal disease for whom lobectomy is technically feasible; other patients should receive definitive chemoradiation. Patients who do not progress after induction therapy and have some evidence of response should have the planned surgical resection. Prognosis is significantly better for patients whose mediastinal disease has been cleared, but proceeding with surgery if N2 disease persists after induction therapy is reasonable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51.

    PubMed  Google Scholar 

  2. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7.

    CAS  PubMed  Google Scholar 

  3. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15(4):504–35.

    Google Scholar 

  4. Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:243S–65S.

    PubMed  Google Scholar 

  5. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998;21:1–6.

    CAS  PubMed  Google Scholar 

  6. Rosell R, Gómez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer. 1999;26:7–14.

    CAS  PubMed  Google Scholar 

  7. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–27.

    CAS  PubMed  Google Scholar 

  8. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–60.

    PubMed  Google Scholar 

  9. Johnstone DW, Byhardt RW, Ettinger D, et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002;54:365–9.

    PubMed  Google Scholar 

  10. Taylor NA, Liao ZX, Cox JD, et al. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004;58:204–12.

    PubMed  Google Scholar 

  11. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–50.

    PubMed  Google Scholar 

  12. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e314S–40S.

    CAS  PubMed  Google Scholar 

  14. Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462–74.

    CAS  PubMed  Google Scholar 

  15. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981–9.

    CAS  PubMed  Google Scholar 

  16. Ito M, Yamashita Y, Tsutani Y, et al. Classifications of N2 non-small-cell lung cancer based on the number and rate of metastatic mediastinal lymph nodes. Clin Lung Cancer. 2013;14:651–7.

    PubMed  Google Scholar 

  17. Pless M, Stupp R, Ris HB, et al. SAKK Lung Cancer Project Group. Induction chemoradiation in stage IIIA/N2 nonsmall-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386:1049–56.

    PubMed  Google Scholar 

  18. Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer. 2012;118:6126–35.

    CAS  PubMed  Google Scholar 

  19. Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, D’Amico TA. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012;93(6):1807–12.

    PubMed  Google Scholar 

  20. Yang CF, Gulack BC, Gu L, Speicher PJ, Wang X, Harpole DH, et al. Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015;150(6):1484–92.

    PubMed  PubMed Central  Google Scholar 

  21. Spicer JD, Shewale JB, Nelson DB, Mitchell KG, Bott MJ, Vallières E, et al. Multimodality therapy for N2 non-small cell lung cancer: an evolving paradigm. Ann Thorac Surg. 2019;107(1):277–84.

    PubMed  Google Scholar 

  22. Veeramachaneni NK, Feins RH, Stephenson BJ, et al. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94:922–6.

    PubMed  Google Scholar 

  23. Tanner NT, Gomez M, Rainwater C, et al. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012;7:365–9.

    PubMed  PubMed Central  Google Scholar 

  24. Berry MF, Worni M, Pietrobon R, D’Amico TA, Akushevich I. Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer. J Thorac Oncol. 2013;8(6):744–52.

    PubMed  PubMed Central  Google Scholar 

  25. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol. 2005;23:3257–69.

    CAS  PubMed  Google Scholar 

  26. Wright CD, Gaissert HA, Grab JD, O’Brien SM, Peterson ED, Allen MS. Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model. Ann Thorac Surg. 2008;85:1857–65.

    PubMed  Google Scholar 

  27. Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg. 2001;72:1149–54.

    CAS  PubMed  Google Scholar 

  28. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.

    CAS  PubMed  Google Scholar 

  29. Garrido P, González-Larriba JL, Insa A, Provencio M, Torres A, Isla D, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol. 2007;25(30):4736–42.

    PubMed  Google Scholar 

  30. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–97.

    CAS  PubMed  Google Scholar 

  31. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.

    PubMed  Google Scholar 

  33. Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–77.

    CAS  PubMed  Google Scholar 

  34. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–92.

    CAS  PubMed  Google Scholar 

  35. Eberhardt WE, Pottgen C, Gauler TC, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33:4194–201.

    CAS  PubMed  Google Scholar 

  36. McElnay PJ, Choong A, Jordan E, Song F, Lim E. Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials. Thorax. 2015;70(8):764–8.

    CAS  PubMed  Google Scholar 

  37. Pottgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) – a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8(25):41670–8.

    PubMed  PubMed Central  Google Scholar 

  38. Ren Z, Zhou S, Liu Z, Xu S. Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis. J Thorac Dis. 2015;7(8):1414–22.

    PubMed  PubMed Central  Google Scholar 

  39. Xu YP, Li B, Xu XL, Mao WM. Is there a survival benefit in patients with stage IIIA (N2) nonsmall cell lung cancer receiving neo-adjuvant chemotherapy and/or radiotherapy prior to surgical resection: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e879.

    CAS  Google Scholar 

  40. Postmus PE, Kerr KM, Oudkerk M, et al. ESMO Guidelines Committee. Early and locally advanced nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv1–iv21.

    CAS  PubMed  Google Scholar 

  41. Yang H, Yao F, Zhao Y, Zhao H. Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer. J Thorac Dis. 2015;7(9):1616–23.

    PubMed  PubMed Central  Google Scholar 

  42. Shintani Y, Funakoshi Y, Inoue M, Takeuchi Y, Okumura M, Maeda H, Ohta M. Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2012;18(6):530–5.

    PubMed  Google Scholar 

  43. Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, Altorki NK. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg. 2011;141(1):48–58.

    PubMed  Google Scholar 

  44. Lee J, Kim HK, Park BJ, Cho JH, Choi YS, Zo JI, et al. Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer. Lung Cancer. 2018;115:89–96.

    PubMed  Google Scholar 

  45. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5):787–98.

    PubMed  Google Scholar 

  46. Jaklitsch MT, Gu L, Demmy T, Harpole DH, D’Amico TA, McKenna RJ, et al. Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. J Thorac Cardiovasc Surg. 2013;146(1):9–16.

    PubMed  PubMed Central  Google Scholar 

  47. De Waele M, Hendriks J, Lauwers P, Hertoghs M, Carp L, Salgado R, et al. Restaging the mediastinum in non-small cell lung cancer after induction therapy: non-invasive versus invasive procedures. Acta Chir Belg. 2011;111(3):161–4.

    PubMed  Google Scholar 

  48. Yang CF, Adil SM, Anderson KL, Meyerhoff RR, Turley RS, Hartwig MG, et al. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. Eur J Cardiothorac Surg. 2016;49(6):1607–13.

    CAS  PubMed  Google Scholar 

  49. Decaluwé H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg. 2009;36(3):433–9.

    PubMed  Google Scholar 

  50. Friedel G, Budach W, Dippon J, Spengler W, Eschmann SM, Pfannenberg C, et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010;28(6):942–8.

    CAS  PubMed  Google Scholar 

  51. Edelman MJ, Hu C, Le QT, Donington JS, D’Souza WD, Dicker AP, et al. Randomized phase II Study of preoperative chemoradiotherapy ± panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (Stage IIIa, N2+) non-small cell lung cancer: NRG Oncology RTOG 0839. J Thorac Oncol. 2017;12(9):1413–20.

    PubMed  PubMed Central  Google Scholar 

  52. Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 2012;84(2):456–63.

    PubMed  Google Scholar 

  53. Jaklitsch MT, Herndon JE 2nd, DeCamp MM Jr, Richards WG, Kumar P, Krasna MJ, et al. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol. 2006;94(7):599–606.

    PubMed  Google Scholar 

  54. Spaggiari L, Casiraghi M, Guarize J, Brambilla D, Petrella F, Maisonneuve P, De Marinis F. Outcome of patients with pN2 “potentially resectable” nonsmall cell lung cancer who underwent surgery after induction chemotherapy. Semin Thorac Cardiovasc Surg. 2016;28(2):593–602.

    PubMed  Google Scholar 

  55. Tanaka F, Yokomise H, Soejima T, Uramoto H, Yamanaka T, Nakagawa K, et al. Induction chemoradiotherapy (50 Gy), followed by resection, for stage IIIA-N2 non-small cell lung cancer. Ann Thorac Surg. 2018;106(4):1018–24.

    PubMed  Google Scholar 

  56. Kamel MK, Rahouma M, Ghaly G, Nasar A, Port JL, Stiles BM, et al. Clinical predictors of persistent mediastinal nodal disease after induction therapy for stage IIIA N2 non-small cell lung cancer. Ann Thorac Surg. 2017;103(1):281–6.

    PubMed  Google Scholar 

  57. Port JL, Korst RJ, Lee PC, Levin MA, Becker DE, Keresztes R, Altorki NK. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg. 2005;79(5):1686–90.

    PubMed  Google Scholar 

  58. Higgins KA, Chino JP, Ready N, Onaitis MW, Berry MF, D’Amico TA, Kelsey CR. Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer. J Thorac Cardiovasc Surg. 2011;142(5):1175–9.

    PubMed  Google Scholar 

  59. Kim HK, Cho JH, Choi YS, Zo JI, Shim YM, Park K, et al. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. Lung Cancer. 2016;96:56–62.

    PubMed  Google Scholar 

  60. Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, et al. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011;74:446–50.

    CAS  PubMed  Google Scholar 

  61. Stefani A, Alifano M, Bobbio A, Grigoroiu M, Jouni R, Magdeleinat P, Regnard JF. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. J Thorac Cardiovasc Surg. 2010;140(2):356–63.

    PubMed  Google Scholar 

  62. Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol. 2008;26(7):1128–34.

    PubMed  Google Scholar 

  63. Agrawal V, Coroller TP, Hou Y, Lee SW, Romano JL, Baldini EH, et al. Lymph node volume predicts survival but not nodal clearance in stage IIIA-IIIB NSCLC. PLoS One. 2017;12(4):e0174268.

    PubMed  PubMed Central  Google Scholar 

  64. Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, et al. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: the importance of pathological response and lymph node ratio. Lung Cancer. 2019;133:136–43.

    PubMed  Google Scholar 

  65. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, et al. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012;94(3):914–20.

    PubMed  PubMed Central  Google Scholar 

  66. Billiet C, Peeters S, Decaluwé H, Vansteenkiste J, Dooms C, Deroose CM, et al. Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 stage III-N2 NSCLC after induction chemotherapy and resection. J Thorac Oncol. 2016;11(11):1940–53.

    PubMed  Google Scholar 

  67. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg. 2008;86(3):912–20.

    PubMed  Google Scholar 

  68. Seder CW, Allen MS, Cassivi SD, Deschamps C, Nichols FC, Olivier KR, et al. Stage IIIA non-small cell lung cancer: morbidity and mortality of three distinct multimodality regimens. Ann Thorac Surg. 2013;95(5):1708–16.

    PubMed  Google Scholar 

  69. Shah AA, Worni M, Kelsey CR, Onaitis MW, D’Amico TA, Berry MF. Does pneumonectomy have a role in the treatment of stage IIIA non-small cell lung cancer? Ann Thorac Surg. 2013;95(5):1700–7.

    PubMed  PubMed Central  Google Scholar 

  70. Kappers I, van Sandick JW, Burgers SA, Belderbos JS, van Zandwijk N, Klomp HM. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided. Lung Cancer. 2010;68(2):222–7.

    PubMed  Google Scholar 

  71. Yamaguchi M, Shimamatsu S, Edagawa M, Hirai F, Toyozawa R, Nosaki K, et al. Pneumonectomy after induction chemoradiotherapy for locally advanced non-small cell lung cancer: should curative intent pulmonary resection be avoided? Surg Today. 2019;49(3):197–205.

    PubMed  Google Scholar 

  72. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R Jr, Livingston RB, Griffin BR, Benfield JR. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg. 1993;105:97–104.

    CAS  PubMed  Google Scholar 

  73. Chen Y, Peng X, Zhou Y, Xia K, Zhuang W. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis. World J Surg Oncol. 2018;16(1):8.

    PubMed  PubMed Central  Google Scholar 

  74. Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9(7):636–48.

    PubMed  Google Scholar 

  75. Bonomi P, Faber LP, Warren W, Lincoln S, LaFollette S, Sharma M, Recine D. Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation. Semin Oncol. 1997;24:S12-123–S112-129.

    Google Scholar 

  76. Fowler WC, Langer CJ, Curran WJ Jr, Keller SM. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg. 1993;55:986–9.

    CAS  PubMed  Google Scholar 

  77. Siegenthaler MP, Pisters KM, Merriman KW, Roth JA, Swisher SG, Walsh GL, et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg. 2001;71:1105–11.

    CAS  PubMed  Google Scholar 

  78. Perrot E, Guibert B, Mulsant P, Blandin S, Arnaud I, Roy P, Geriniere L, Souquet PJ. Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection. Ann Thorac Surg. 2005;80:423–7.

    PubMed  Google Scholar 

  79. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929–37.

    CAS  PubMed  Google Scholar 

  80. Evans NR 3rd, Li S, Wright CD, Allen MS, Gaissert HA. The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer. J Thorac Cardiovasc Surg. 2010;139(4):991-6.e1–2.

    Google Scholar 

  81. Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg. 2004;78:1200–5.

    PubMed  Google Scholar 

  82. Deutsch M, Crawford J, Leopold K, Wolfe W, Foster W, Herndon J, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer. 1994;74:1243–52.

    CAS  PubMed  Google Scholar 

  83. Edelman MJ, Hu C, Le QT, Donington JS, D’Souza WD, Dicker AP, Loo BW, Gore EM, Videtic GMM, Evans NR, Leach JW, Diehn M, Feigenberg SJ, Chen Y, Paulus R, Bradley JD. Randomized phase II study of preoperative chemoradiotherapy ± panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (Stage IIIa, N2+) non-small cell lung cancer: NRG Oncology RTOG 0839. J Thorac Oncol. 2017;12(9):1413–20.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University, Stanford, CA, USA

    Mark F. Berry

Authors
  1. Mark F. Berry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark F. Berry .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Chicago, Chicago, IL, USA

    Mark K. Ferguson

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Berry, M.F. (2020). Is Resection of Persistent N2 Disease After Induction Therapy Effective?. In: Ferguson, M. (eds) Difficult Decisions in Thoracic Surgery. Difficult Decisions in Surgery: An Evidence-Based Approach. Springer, Cham. https://doi.org/10.1007/978-3-030-47404-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-47404-1_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-47403-4

  • Online ISBN: 978-3-030-47404-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation